Admin Password
Forskning, artikler og dokumenter, som betvivler de forskningsartiklers gyldighed og pålidelighed, som myndigheder vælger at benytte mht. HPV-vaccinen:
• (2007) [Dream vaccine or still a dream?]
- Drømmevaksine eller fortsatt en drøm?
"Produsenter av HPV-vaksiner vil tjene store penger hvis Norge og andre land går inn for å vaksinere alle jenter. Hvorfor har helsemyndighetene slikt hastverk?" |
• (2007) [The HPV vaccine--still no answers to important questions]
- HPV-vaksinen – fortsatt viktige ubesvarte spørsmål |
• (2007) Cancer-virus vaccine targets wrong age group
"“The number one problem with the vaccine is that it has not been tested adequately on the group that is recommended to get it,” said Dr. Joseph DeSoto, a fellow in the American Institute of Chemists and a physician-scientist at the National Institutes of Health." |
• (2007) Life saving treatment or giant experiment?
"One Merck funded researcher, Diane Harper, has received publicity for saying that giving the vaccine to 11 year old girls is “a great big public health experiment.”" | |
• (2008) Examining the FDA’s HPV Vaccine Records - Detailing the Approval Process, Side-Effects, Safety Concerns and Marketing Practices of a Large-Scale Public Health Experiment
• (2009) Drugs, sex, money and power: An HPV vaccine case study
• (2009) Germany reviews its policy on HPV vaccination for 12-17 year olds
"Germany’s Robert Koch Institute is reviewing its recommendation that all 12-17 year old girls should be vaccinated against the human papillomavirus (HPV) to reduce the risk of cervical cancer, after criticism from experts.
A group of 13 medical scientists publicly criticised the institute’s recommendation in November 2008 (Sueddeutsche Zeitung, 26 Nov)."
• (2009) Marketing HPV vaccine: implications for adolescent health and medical professionalism
"The vaccine manufacturer also provided educational grants to professional medical associations (PMAs) concerned with adolescent and women's health and oncology. The funding encouraged many PMAs to create educational programs and product-specific speakers' bureaus to promote vaccine use. However, much of the material did not address the full complexity of the issues surrounding the vaccine and did not provide balanced recommendations on risks and benefits."
• (2010) HPV Vaccines Mechanisms of Action in Women |
• (2011) The Creating of an HPV Industry
• (2012) An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women
• (2012) No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil?
• (2012) Pharmaceutical companies' role in state vaccination policymaking: the case of human papillomavirus vaccination |
• (2012) Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil
• (2013) HPV vaccines and cancer prevention, science versus activism
• (2013) Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds?
• (2014) Confirmation of the creation of a novel molecule in Gardasil
• (2016) Complaint filed to the European Medicines Agency over maladministration related to safety of the HPV vaccines
• (2016) Human papillomavirus vaccines, complex regional pain syndrome, postural orthostatic tachycardia syndrome, and autonomic dysfunction – a review of the regulatory evidence from the European Medicines Agency
• (2016) New Concerns about the Human Papillomavirus Vaccine
• (2017) Betrayal of Public Trust & Institutional Corruption: Vaccine Safety Ratings & Vaccine Science Falsified
• (2017) Ensidig HPV-kampagne
"Sundhedsstyrelsen (SST), Kræftens Bekæmpelse og Lægeforeningen relancerer nu vaccinationsprogrammet rettet mod human papillomvirus. Det er en massiv kampagne, der formentlig er tænkt som information, men en række oplysninger fremstår som fordrejede i forhold til realiteterne, og vigtig viden er helt udeladt." | |
• (2017) Lessons learnt in Japan from adverse reactions to the HPV vaccine: a medical ethics perspective
• (2017) Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance
"...the safety of HPV vaccines is in doubt on the basis of reported adverse effects associated to autoimmune events hypothetically connected to molecular mimicry mechanism. However, several studies conducted to date have not been able to provide robust evidence to support these safety concerns, which have been reported as barriers to preventive HPV vaccination but justify continued surveillance of autoimmune diseases (ADs) following exposure to HPV vaccines."
• (2017) Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?
• (2017) Vaccinerne har ikke halveret nye tilfælde af livmoderhalskræft
• (2017) What the Gardasil Testing May Have Missed
• (2018) Challenges of independent assessment of potential harms of HPV vaccines
• (2018) Cochrane HPV vaccine review: BMJ journal defends “inconvenient criticisms”
Artikel i det videnskabelige tidsskrift The Lancet, udgivet tidligere i denne måned:
• (2018) Cochrane review methods called into question - Cochrane is contesting allegations that a human papillomavirus vaccine review missed 20 eligible trials in its analysis.
- "“There is extensive literature showing extensive bias in publications; that is why we go to manufacturers and regulators instead”, Jefferson told The Lancet. “It is a completely different paradigm; you are talking about a database of 65000 pages of regulatory data instead of the handful of pages and selective data that appears in a journal.”
He added that even the thousands of regulatory data only represent a fraction of all the information generated by studies of the HPV vaccine. The BMJ EBM article authors believe that published trial documents do not offer a complete picture of any given intervention; they contend that data on serious harms, for example, is often excluded."
- "“It is about data”, Jefferson told The Lancet. “Some of the HPV trials are not even registered on; they are completely invisible we only found them because we went through thousands of pages of FDA documents and saw them mentioned”."
• (2018) Denmark: Pushing back in Europe
"Whatever the outcome, the work of Drs. Brinth and Mehlsen, and their colleagues deserves close examination, as does Vigibase data on adverse events. Epidemiological studies, currently cited to dispel associations with side effects, are alone insufficient. More basic science research is needed."
• (2018) HPV vaccine safety: Cochrane launches urgent investigation into review after criticisms
• (2018) Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review
"...only half (38/79, 48%) of the manufacturers’ randomized clinical trials and follow-ups of Cervarix and Gardasil completed before the submission dates in July 2015 were included (EMA’s review did not assess Gardasil 9). Similarly, the FDA’s Drug Approval Packages (DAPs) only mentioned half (32/60, 53%) of the randomized clinical trials and follow-ups that were completed before the vaccines’ date of the Drug Approval Packages (Cervarix: 17/36, 47%; Gardasil: 6/11, 54%; and Gardasil 9: 9/13, 69%). We find this very disturbing."
• (2018) Peter Gøtzsche: Derfor blev jeg fyret fra bestyrelsen i Cochrane. Men kampen fortsætter
"Men så kom vor forskning om hpv-vaccinerne bestyrelsesformanden til hjælp. Selv om bestyrelsen benægter det, er det en kendsgerning, at denne forskning spillede en central rolle for min eksklusion fra Cochrane.
I maj 2018 udkom den længe ventede og stærkt prestigefyldte Cochrane-oversigt om hpv-vaccinerne. Den er problematisk.
I modstrid med Cochranes regler var der alt for mange forskere med finansielle interessekonflikter på protokollen til oversigten, Cochrane havde publiceret, og efter internationale protester blev man nødt til at smide de fleste på porten.
Min forskergruppe ved mere om emnet end de fleste, fordi vi laver forskning på de studierapporter om hpv-vaccinerne, vi har fået fra Det Europæiske Lægemiddelagentur.
Disse rapporter kan være på flere tusind sider per forsøg, og de er langt mere pålidelige end de korte artikler, firmaerne publicerer, især med hensyn til skadevirkninger. Vi offentliggjorde vor kritik af Cochrane-oversigten 27. juli i BMJ Evidence-Based Medicine.
Vi påviste bl.a., at der manglede mange studier og patienter i Cochrane-oversigten. Vor kritik blev ilde modtaget af Cochranes to chefredaktører, som mente, den var overdrevet.
Det var den ikke, og 17. september publicerede vi en endnu skarpere kritik i samme tidsskrift efter at have gravet endnu dybere i materialet."
• (2018) Professor Peter Gøtzsche om vaccinemodstandere: Den hårde kerne er resistente over for rationelle argumenter - »Vi er ikke længere store aber i Afrika«, der har godt af lidt mæslinger, mener professor Peter Gøtzsche. I ny bog går han voldsomt i rette med vaccinemodstandere. Gøtzsche støtter alle de almindelige børnevacciner, men helt så enkelt er det ikke med HPV-vaccinerne. Læs fuldt kapiteluddrag fra bogen.
"Jeg må indrømme, at efter at have studeret, hvad der foregår bag lukkede døre, har jeg indset, hvorfor så mange mennesker er skeptiske over for vacciner. Nogle af de hårdeste skeptikere er ikke rationelle, men nogle er givetvis. Vi skal stille spørgsmål. Der er mange eksempler på, at lægerne har været aktivt frarådet af myndighederne at rapportere mistænkte alvorlige skader af vacciner, hvoraf det seneste WHO-initiativ nævnt ovenfor nok er det værste." | |
• (2018) The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias

Forskning, artikler og dokumenter, som kritiserer måden myndighederne samt medierne har håndteret bivirkninger af HPV-vaccinen på:
• (2010) November 17, 2010: Vaccines and Related Biological Products Advisory Committee Meeting Transcript
"Over 20,000 families are now begging for help, and no one is answering their desperate pleas." |
• (2015) Sundhedsstyrelsens kritisable adfærd i HPV-bivirkningssagen
• (2016) A qualitative study of women who experience side effects from human papillomavirus vaccination
"The women reported feeling stigmatised by GPs and doctors and they felt that these professionals did not acknowledge their symptoms, often assuming that they were due to psychological distress. The lack of acceptance from family and friends had led the women to distance themselves from others and lead a more socially isolated life." | |
• (2016) Posting Official Documents on HPV Vaccine Cover Up by Officials |
• (2017) Re: Discussing human papilloma virus vaccination
"Such is the amount of misinformation in the medical and public press, and so large are the profits to be made - “Gardasil brought in $1.7billion for Merck “ that Tom Jefferson, reviewer for the Cochrane Collaboration, and vaccine expert, remarked that “the HPV vaccines’ benefits have been hyped, and the harms hardly investigated. It is extremely difficult to publish anything against HPV vaccination. Vaccines have become like a religion. They are not something you question. If you do, you are seen as an anti-vaccine extremist.“" |
• (2017) Govt. Still Pushing HPV Vaccine on Kids a Decade after JW Exposed Deadly Side Effects
• (2017) How Silencing of Dissent in Science Impacts Woman. The Gardasil® Story
"The issues of safety and efficacy of certain vaccines remains extremely contentious. The venues for this debate have included periodicals, documentary films, and an ever-increasing number of on-line sites. While debate in science is not only a common occurrence but a fundamental tenet of the scientific community, it only works when divergent opinions can be heard. When those who hold an opposing opinion are denigrated and/or marginalized by those holding the majority opinion such as in the issue of vaccination, where cultural authority for the issue is owned by the profession of medicine, both science and the public lose." |
• (2018) A global girl gang
"Symptoms suspected to be caused by HPV vaccination, such as those portrayed in Sacrificial Virgins, need empathy, counselling, and support. The questions, symptoms, and concerns are real for those who experience them and dismissing them as being unrelated to vaccination will only provoke more distrust and alienation. Disseminating better messages is not the point. These stories are about a broken relationship and need repair. They need listening, not instructing. They need dialogue, not dismissal."

Forskning, artikler og dokumenter, som betvivler HPV-vaccinens grundlag, gyldighed og effektivitet, generelt, på kort (surrogate endpoints) og på lang (type replacement & virulence) sigt:
• (2006) HIGHLIGHTS OF PRESCRIBING INFORMATION - GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
"The duration of immunity following a complete schedule of immunization with GARDASIL has not been established."
• (2007) Democracy, or Orson Welles' 1984?
"Gardasil cannot yet be proven to be a life saver. As an article on line ( ) states:
"...In the studies that led to the vaccine's approval, the incidence of cervical cancer was not measured. Instead CIN (cervical intraepithelial neoplasia) 2/3 and AIS (adenocarcinoma in situ) were used as the surrogate markers for prevention of cervical cancer because according to the vaccine's insert "CIN 2/3 and AIS are the immediate and necessary precursors of squamous cell carcinoma and adenocarcinoma of the cervix, respectively." While this is true it is also true that CIN 2/3 and AIS usually do not lead to cancer. For example, according to published data, CIN2 only leads to invasive carcinoma 5% of the time and CIN3 only leads to invasive carcinoma 12% of the time." ( Arends MJ, et al., Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol. 1998 Feb;51(2):96-103. Available here:
This article goes on to point out that:
"...during discussions at the FDA it was admitted that HPV alone is insufficient to cause cancer. Dr. Elizabeth Unger of the Centers for Disease Control stated, "So it is believed that infection alone is insufficient to cause cancer, and additional factors are required for neoplasia. There are certainly lots of questions about HPV infection…" (Dr. Beth Unger. See Minutes from: FDAVaccines and Related Biological Products Advisory Committee, November 28, 2001, p. 21 available here:
… and that:
"....If HPV alone caused cervical cancer than the number of cases in the U.S. would be the same as the number of women with HPV infections. Since only a relatively small percentage of HPV infected women get cervical cancer this raises the question whether a vaccine against HPV is the right target at all? In fact, according to the text Cancer: Principles & Practice of Oncology, "In most studies, HPV status was not a strong independent prognosticator of outcome in cervical cancer patients; however there appears to be a trend for HPV-negative tumors to do worse …those tumors containing HPV DNA tend to be of an early stage and low grade.." (Vincent T. Devita, Jr., et al., editors, Cancer Principles & Practice of Oncology, 6th edition, volume2, p. 1523)"
• (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial
"Most HPV infections, regardless of type, clear spontaneously, typically within 6 months to 2 years." ... "Results from our community-based study provide strong evidence that there is little, if any, therapeutic benefit from the vaccine in the population we studied." |
• (2008) Human Papillomavirus Vaccination — Reasons for Caution
"As Kim and Goldie point out in this issue of the Journal, the real impact of HPV vaccination on cervical cancer will not be observable for decades." ... "How will the vaccine affect other oncogenic strains of HPV? If HPV-16 and HPV-18 are effectively suppressed, will there be selective pressure on the remaining strains of HPV? Other strains may emerge as significant oncogenic serotypes."
• (2009) The Risks and Benefits of HPV Vaccination
"But the net benefit of the HPV vaccine to a woman is uncertain. Even if persistently infected with HPV, a woman most likely will not develop cancer if she is regularly screened."
• (2010) A long story made too short: surrogate variables and the communication of HPV vaccine trial results /
• (2010) Cervical cancer incidence can increase despite HPV vaccination
• (2010) Post-licensure monitoring of HPV vaccine in the United States
"While there are well established cancer registries in the United States, it will take decades before the impact of vaccine on cervical cancer is observed."
• (2010) Review of Gardasil
"We do not know how long the vaccine will last, the HPV types covered by the vaccine are limited, and the very safe alternative of Pap screening with early detection and treatment is a proven successful program."
• (2011) Evolutionary Ecology of Human Papillomavirus: Trade-offs, Coexistence, and Origins of High-Risk and Low-Risk Types
"Conclusions. Our results indicate that the elimination of HR HPV through vaccines may alter the evolutionary trajectory of the remaining types and promote evolution of new HR HPV types."
• (2011) How Effective Is the HPV Vaccine at Preventing Cancer? A Closer Look...
"The data currently rely on surrogate end points (markers of possible cancer) and are simply not conclusive. So we can’t truly say how effective the vaccine is."
• (2011) Letter to the Editor Response to the article of Luisa Lina Villa HPV prophylactic vaccination: The first years and what to expect from now
"First Villa did not cite figures effectiveness of vaccines in per protocol groups against CIN2/3 caused by all HPV. These numbers are absolutely essential to know the real capacity of these vaccines to prevent cancer of the cervix because of the theoretical possibility of viral replacement."
• (2011) We need to talk about HPV vaccination – seriously
"There is another serious question that may be answered sooner: what effect will the vaccine have on the other cancer-causing strains of HPV? Nature never leaves a void, so if HPV-16 and HPV-18 are suppressed by an effective vaccine, other strains of the virus will take their place. The question is, will these strains cause cervical cancer?
Results from clinical trials are not encouraging. Vaccinated women show an increased number of precancerous lesions caused by strains of HPV other than HPV-16 and HPV-18." ... "With so many essential questions unanswered, there is good reason to be cautious about introducing large-scale HPV vaccination. Instead, we should concentrate on getting answers."
• (2012) Who Profits From Uncritical Acceptance of Biased Estimates of Vaccine Efficacy and Safety?
"...nor that the current overly optimistic surrogate marker–based extrapolations are justified." |
• (2013) HPV vaccination programs have not been shown to be cost-effective in countries with comprehensive Pap screening and surgery
• (2013) Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe?
"For example, the claim that HPV vaccination will result in approximately 70% reduction of cervical cancers is made despite the fact that the clinical trials data have not demonstrated to date that the vaccines have actually prevented a single case of cervical cancer (let alone cervical cancer death)..."
• (2013) Individual karyotypes at the origins of cervical carcinomas
"Based on our findings it is expected that a vaccine against human papilloma viruses will have no effect on the occurrence of cervical carcinomas."
• (2014) Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada
"No invasive cancers were detected in either cohort, but 12 vaccinated females (0.3%) and 22 nonvaccinated females (0.2%) had CIS [(cancer in situ)] during follow-up."
• (2014) HPV Vaccination in India: Critical Appraisal
"As it is very difficult to determine that in which person HPV infection will persist and lead to disease progression because most of the HPV infection resolve spontaneously, the usefulness of HPV vaccination is dubious." ... "However it is clear that cervical cancer vaccine is not an immediate panacea and cannot replace the cervical cancer screening which is mandatory in Indian context."
• (2014) Reduction in HPV prevalence--no evidence to support HPV vaccination reduces HPV prevalence
"The HPV4 published studies to date use antibody titers as the surrogate endpoint for efficacy, an unsupported endpoint as there is no immunologic surrogate of protection yet identified."
• (2014) Revising ecological assumptions about Human papillomavirus interactions and type replacement
"Our results suggest that independence between types could be a fallacy, and so without conclusively untangling HPV within-host ecology, type replacement remains theoretically viable."
• (2015) Begrænset fordel af HPV-vaccination af drenge
• (2015) Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20–26 years)
"The prevalence of high-risk nonvaccine types was higher among vaccinated women than unvaccinated women (52.1% vs 40.4%, prevalence ratio 1.29, 95% CI 1.06–1.57)..."
• (2015) Could the human papillomavirus vaccines drive virulence evolution?
"Here, we present and theoretically validate a mechanism by which the vaccine alters the transmission–recovery trade-off that constrains HPV's virulence such that higher oncogene expression is favoured." |
• (2015) The impact of HPV vaccination on future cervical screening: a simulation study of two birth cohorts in Denmark
"Conclusions: In our calculations, the proportion of positive screening results with liquid-based cytology will be reduced as a consequence of HPV vaccination, but the reduction is small, and the expected decline in PPV [(positive predictive value)] is very limited."
• (2016) High-Risk HPV Type Replacement Follows HPV Vaccination
• (2016) HPV vaccines: a controversial issue?
"Since the quadrivalent HPV vaccine was approved by the FDA in the USA in June 2006, it will take at least another 15-20 years before the long-term efficacy of these vaccines becomes evident." ... "We also strongly believe that a regular systematic review of the literature by qualified individuals with no financial interests should be conducted. In many instances, financial resources originate from parties within the competitive HPV vaccine market, which certainly have economic interests, causing major complications in interpreting the results and conclusions from the various studies." |
• (2016) Ledende overlæge: Sundhedsstyrelsen vildleder om HPV-vaccine |
- Ekspert anklager styrelse for at vildlede om HPV-vaccine
"»Det er bevist, at vaccinen nedsætter antallet af infektioner med HPV og antallet af tilfælde med celleforandringer, hvilket man kalder surrogat-endepunkter. Men det er ikke bevist, at vaccinen beskytter mod livmoderhalskræft,« siger Varming."
• (2016) Shift in prevalence of HPV types in cervical cytology specimens in the era of HPV vaccination
"Consequently, the present study hypothesizes that there may be a continuous shift in the prevalence of HPV types as a result of vaccination. Furthermore, the percentage of non-vaccine HR-HPV types was higher than expected, considering that eight HPV types formerly classified as 'low-risk' or 'propably high-risk' are in fact HR-HPV types." |
• (2017) Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014
"CONCLUSION: An increasing incidence of OPSCC is driven primarily by HPV+ OPSCC. Sixty-two percent of tumours were HPV+, which is a high-prevalence, although the lower number of HPV- cases has yet to stabilise. HPV16 was the predominant genotype..."
- Sunde mænd får pludselig alvorlig kræftform - HPV får skylden
• (2017) Endocervical Carcinogenesis and HPV Vaccination: An Occasional Circumstance or a Gap in the Chain?
"We present a case of cervical adenocarcinoma in situ (AIS) in a 30-year-old female with a positive HPV 16 typing test though fully vaccinated against HPV after the onset of her sexual life. This is a rare incident that is raising many questions about the efficacy and the safety of HPV vaccines." |
• (2017) HPV-vaccinerede bør stadig blive screenet for livmoderhalskræft
"Beregningerne viser, at antallet af positive screeningssvar kommer til at falde med cirka 2 procentpoint i den vaccinerede del sammenlignet med den ikke-vaccinerede del." ... "Resultatet giver også et hint om, at screening kan medføre en del overbehandling, mener lektor Henrik Støvring, der forsker i effekten af forskellige screeningsprogrammer på Aarhus Universitets Institut for Folkesundhed." ... "Konsekvensen er, at en del kvinder får fjernet celleforandringer, der sikkert aldrig ville have medført sygdom." ... "»Det er lige godt mærkeligt, at der ikke sker en større ændring i antallet af positive testsvar hos den vaccinerede del af befolkningen, tænkte jeg, da jeg først så studiet,« siger Henrik Støvring, som har læst den videnskabelige artikel."
• (2017) Preventing Cervical Cancer - Investigating costs, access, marketing, and effectiveness of vaccines
"We will not know for years how effectively HPV vaccines actually prevent cervical and related cancers or how the population of viral serotypes adapts."
• (2017) Re: UK doctors re-examine case for mandatory vaccination
"UK Government statistics (ONS England) and (ISD Scotland) for cervical cancer are showing a consistent increase in cases of cervical cancer in the 20-24 age group in recent years (2012-2015), in Scotland the number of cases has more than tripled in comparison with the period 2006-2008, before the vaccine was introduced. Also vaccinated girls and women, as young as 18, are being diagnosed with cervical cancer."
• (2018) Cervical cancer statistics - Cervical cancer in Australia
"In 2013, there were 813 new cases of cervical cancer diagnosed in Australia. In 2018, it is estimated that 930 new cases of cervical cancer will be diagnosed in Australia. In 2013, the age–standardised incidence rate was 6.8 cases per 100,000 females. In 2017, it is estimated that the age–standardised incidence rate will be 7.1 cases per 100,000 females."
• (2018) Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis
"Most CIN2 lesions, particularly in young women (<30 years), regress spontaneously."

Generelt mht. surrogat-endepunkters pålidelighed:
• (2005) Surrogate Endpoints And FDA’s Accelerated Approval Process
"Unfortunately, demonstrating treatment effects on these biological “surrogate” endpoints, while clearly establishing biological activity, may not provide reliable evidence about effects of the intervention in clinical efficacy measures."
• (2015) Mange kræftstudier med surrogatendemål viser lav overlevelse - Kræftmidler, der er blevet godkendt på baggrund af surrogate endemål viser sig ofte ikke at forbedre overlevelsen. Det konkluderer en artikel i JAMA Internal Medicine.
• (2017) Surrogate markers may not tell the whole story

Forskning, artikler og dokumenter, som betvivler HPV-vaccinens sikkerhed:
• (2008) [Two unclear cases of death. Can we still recommend HPV vaccination?]
• (2008) Anaphylaxis following quadrivalent human papillomavirus vaccination
"Based on the number of confirmed cases, the estimated rate of anaphylaxis following quadrivalent HPV vaccine was significantly higher than identified in comparable school-based delivery of other vaccines." |
• (2008) Brachial plexus neuritis following HPV vaccination |
• (2008) Development of unilateral cervical and supraclavicular lymphadenopathy after human papilloma virus vaccination
• (2008) Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study
"35 schoolgirls with suspected hypersensitivity to the quadrivalent human papillomavirus vaccine were notified to the specialised immunisation services in 2007, after more than 380 000 doses had been administered in schools. Of these 35 schoolgirls, 25 agreed to further evaluation. Twenty three (92%) experienced reactions after the first dose." ... "In conclusion, suspected hypersensitivity reactions to the human papillomavirus quadrivalent vaccine require further evaluation to exclude IgE mediated reactions." ... "Our clinical recommendation is that females with suspected hypersensitivity to the quadrivalent vaccine should be evaluated before receiving more doses, and any challenges with the same vaccine should be carried out in a supervised setting." |
• (2008) Meningococcal and human papilloma virus vaccine associated recurrent acute disseminated encephalomyelitis
• (2008) Pancreatitis following human papillomavirus vaccination
• (2008) The human papillomavirus vaccine and risk of anaphylaxis
"The HPV vaccine is associated with high rates of fainting in adolescents, which can result in serious head injuries." |
• (2009) A report of five cases of CNS demyelination after quadrivalent human papilloma virus vaccination: could there be any relationship? |
• (2009) Acute Disseminated Encephalomyelitis following vaccination against Human Papilloma Virus
• (2009) Ampiginous choroiditis following quadrivalent human papilloma virus vaccine
• (2009) Cervical cancers after human papillomavirus vaccination
• (2009) CNS demyelination and quadrivalent HPV vaccination
• (2009) Gardasil Researcher Speaks Out
"Parents and women must know that deaths occurred. Not all deaths that have been reported were represented in Dr. Slade's work, one-third of the death reports were unavailable to the CDC, leaving the parents of the deceased teenagers in despair that the CDC is ignoring the very rare but real occurrences that need not have happened if parents were given information stating that there are real, but small risks of death surrounding the administration of Gardasil."
• (2009) Immune thrombocytopenic purpura following human papillomavirus vaccination
• (2009) Opsoclonus Myoclonus after human papilloma virus vaccine in a pediatric patient
• (2009) Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine
• (2009) Quadrivalent Human Papillomavirus recombinant vaccine associated lipoatrophy
• (2009) Quantifying the possible cross-reactivity risk of an HPV16 vaccine
• (2010) A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus
• (2010) Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus
• (2010) Demyelinating disease and polyvalent human papilloma virus vaccination
• (2010) Erythema multiforme following vaccination for human papillomavirus
• (2010) Postural tachycardia syndrome after vaccination with Gardasil |
• (2010) The quadrivalent human papillomavirus vaccine: erythema multiforme and cutaneous side effects after administration
• (2011) [Demyelinating disease and vaccination of the human papillomavirus]
• (2011) A Catastrophic Failure
"A 17-year-old woman presented to the emergency department with a 4-day history of abdominal pain, nausea, and vomiting. Her symptoms started after she received the human papillomavirus vaccine 1 week earlier." ... "Our patient had no prodromal symptoms, but the fulminant myocarditis was after she received the human papillomavirus vaccine."
• (2011) Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl
• (2011) Bilateral papilledema following human papillomavirus vaccination
• (2011) Brachial neuritis following quadrivalent human papilloma virus (HPV) vaccination |
• (2011) Guillain–Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006–2009
• (2011) Potential cross-reactivity between HPV16 L1 protein and sudden death-associated antigens
• (2011) Syncope and seizures following human papillomavirus vaccination: a retrospective case series
• (2012) Death after Quadrivalent Human Papillomavirus (HPV) Vaccination: Causal or Coincidental?
"Conclusions: Our study suggests that HPV vaccines containing HPV-16L1 antigens pose an inherent risk for triggering potentially fatal autoimmune vasculopathies." | |
• (2012) Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil
• (2012) Detection of human papillomavirus L1 gene DNA fragments in postmortem blood and spleen after Gardasil vaccination — A case report
• (2012) DNA Contamination in HPV vaccines
• (2012) HPV vaccines and autoimmune diseases |
• (2012) Human papillomavirus vaccination, induced autoimmunity, and neuromyelitis optica
• (2012) Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80
• (2012) Kikuchi-Fujimoto disease following vaccination against human papilloma virus infection and Japanese encephalitis
• (2012) Neuromyelitis Optica Following Human Papillomavirus Vaccination
• (2012) Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination
• (2012) Systemic lupus erythematosus following HPV immunization or infection?
• (2012) Telogen effluvium following bivalent human papillomavirus vaccine administration: a report of two cases
• (2012) Vasculitis following HPV immunization
• (2013) Association of acute cerebellar ataxia and human papilloma virus vaccination: a case report
• (2013) Human Papilloma Virus Vaccine and Primary Ovarian Failure: Another Facet of the Autoimmune/Inflammatory Syndrome Induced by Adjuvants
• (2013) Human papillomavirus vaccine and systemic lupus erythematosus
• (2013) Topological conformational changes of human papillomavirus (HPV) DNA bound to an insoluble aluminum salt — A study by low temperature PCR
"Who knows how many young women taking oral contraceptives will experience primary ovarian failure, or POTS (postural orthostatic tachycardia syndrome) following vaccination for HPV?" |
• (2014) A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder?
• (2014) Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice
• (2014) Bivalent HPV vaccine safety depending on subtypes of juvenile idiopathic arthritis
• (2014) Clinical Features in Patients with Long-Lasting Macrophagic Myofasciitis
"Several observations of girls developing fatigue/myalgias syndrome after HPV vaccination raised the question of possible MMF induced by this vaccine." |
• (2014) Early cervical myelitis after human papilloma virus vaccination
• (2014) Fibromyalgia-Like Illness in 2 Girls After Human Papillomavirus Vaccination
• (2014) HIGHLIGHTS OF PRESCRIBING INFORMATION - GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
"Serious adverse events were collected throughout the entire study period (range one month to 48 months post-last dose) for the seven clinical studies for GARDASIL 9. Out of the 15,705 individuals who were administered GARDASIL 9 and had safety follow-up, 354 reported a serious adverse event; representing 2.3% of the population."
• (2014) Human papilloma virus vaccine associated uveitis
• (2014) On the relationship between human papilloma virus vaccine and autoimmune diseases
• (2014) Peripheral Sympathetic Nerve Dysfunction in Adolescent Japanese Girls Following Immunization with the Human Papillomavirus Vaccine
• (2014) Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the “Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants”: Case Report and Literature Review
• (2014) Postural tachycardia syndrome following human papillomavirus vaccination
• (2014) The spectrum of post-vaccination inflammatory CNS demyelinating syndromes
• (2015) [Neurologic Complications in HPV Vaccination]
• (2015) A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events |
• (2015) A critical analysis of the Australian government’s rationale for its vaccination policy |
• (2015) A link between human papilloma virus vaccination and primary ovarian insufficiency: current analysis
• (2015) Adverse Reactions to Human Papillomavirus Vaccines
• (2015) Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: a call for personalised medicine
• (2015) Biopersistence and Brain Translocation of Aluminum Adjuvants of Vaccines
"We previously showed that poorly biodegradable aluminum-coated particles injected into muscle are promptly phagocytosed in muscle and the draining lymph nodes, and can disseminate within phagocytic cells throughout the body and slowly accumulate in brain. This strongly suggests that long-term adjuvant biopersistence within phagocytic cells is a prerequisite for slow brain translocation and delayed neurotoxicity." ... "Alum particles may also bind undesirable residual products inherent to vaccine production procedures, as shown for HPV DNA sequences..." |
• (2015) Canadian academic’s call for moratorium on HPV vaccine sparks controversy
"Geneviève Rail, a professor of critical studies of health at Montreal’s Concordia University, has a $C273 359 grant from the Canadian Institutes of Health Research for research entitled “HPV vaccination discourses, spaces and biopedagogies: Affects and effects on youth’s bodies and subjectivities.” She reports having gathered 170 families whose recounted stories indicate a heavy burden of vaccine injury.
Writing in the Quebec daily newspaper Le Devoir, Rail and her coauthor Abby Lippman, a former professor in McGill University’s department of epidemiology, biostatistics, and occupational health, argued that the vaccine was given to schoolgirls without obtaining proper informed consent. They said that it had caused serious adverse events around the world, that Canada’s system of reporting was inadequate to detect problems, that it was a misplaced priority because cervical cancer was not a leading cause of death, that its efficacy was not proven, that it may even exacerbate precancerous lesions, and that it was fraudulently marketed and too hastily approved."
• (2015) Complex regional pain syndrome and dysautonomia in a 14-year-old girl responsive to therapeutic plasma exchange
• (2015) HPV vaccine Gardasil has a dark side, Star investigation finds |
• (2015) HPV vaccination syndrome. A questionnaire-based study
• (2015) Human Papillomavirus (HPV) Vaccination: Just the Facts
"However, there are a significant number of postvaccinated Japanese girls suffering from chronic headache, fatigue, limb pain, and/or tremor with disability."
• (2015) Human Papillomavirus (HPV) Vaccination Safety Assessment: The Methods Matter
"Wilson disease and Huntington disease are representative disorders involving involuntary limb movement and mental retardation in adolescents; however, these well-known diseases do not induce the type of intractable limb pain, such as CRPS, seen in post-vaccinated Japanese girls. CRPS itself is reported to occur rarely in adolescent girls. The clinical picture of the involved girls is therefore considered to be very unique."
• (2015) Hypothesis: Human papillomavirus vaccination syndrome--small fiber neuropathy and dysautonomia could be its underlying pathogenesis
• (2015) Is Chronic Fatigue Syndrome/Myalgic Encephalomyelitis a Relevant Diagnosis in Patients with Suspected Side Effects to Human Papilloma Virus Vaccine?
• (2015) Lichenoid drug eruption after human papillomavirus vaccination
• (2015) Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus
• (2015) Panuveitis With Exudative Retinal Detachments After Vaccination Against Human Papilloma Virus.
• (2015) Pityriasis rosea following human papillomavirus vaccination
• (2015) Report from the Danish Health and Medicines Authority for consideration by EMA and rapporteurs in relation to the assessment of the safety profile of HPV-vaccines
"Evaluation of data from WHO shows that although the number of cases for POTS is very high in Denmark, compared to the rest of the world, the symptom patterns seen in the Danish dataset is similar to reports submitted from many other countries." | |
• (2015) Subacute autonomic, endocrine, and cognitive disorders in Japanese girls at puberty after human papillomavirus vaccination
• (2015) Suspected side effects to the quadrivalent human papilloma vaccine
• (2015) The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems
• (2015) The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases
• (2015) Vaccines, adjuvants and autoimmunity
• (2016) A case of systemic lupus erythematosus (SLE) following Human papillomavirus (HPV) vaccination
• (2016) Acute Disseminated Encephalomyelitis Following Immunization with Human Papillomavirus Vaccines |
• (2016) Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil
• (2016) Cognitive dysfunction and regional cerebral blood flow changes in Japanese females after human papillomavirus vaccination
• (2016) From HBV to HPV: Designing vaccines for extensive and intensive vaccination campaigns worldwide
"The data 1) support the possibility of crossreactions between the two viral antigens and human proteins that, when altered, may associate with neuropsychiatric, cardiovascular and metabolic diseases such as multiple sclerosis, amyotrophic lateral sclerosis, diabetes, and sudden death..."
• (2016) Human papilloma virus vaccination and dysautonomia: Considerations for autoantibody evaluation and HLA typing
• (2016) Immunological studies of cerebrospinal fluid from patients with CNS symptoms after human papillomavirus vaccination
• (2016) Motor and sensory clinical findings in girls vaccinated against the human papillomavirus from Carmen de Bolivar, Colombia
• (2016) [RETRACTED] Murine hypothalamic destruction with vascular cell apoptosis subsequent to combined administration of human papilloma virus vaccine and pertussis toxin |
• (2016) Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry
• (2016) Postural Orthostatic Tachycardia Syndrome (POTS) – A novel member of the autoimmune family
• (2016) Postural tachycardia syndrome (POTS) with anti-NMDA receptor antibodies after human papillomavirus vaccination
• (2016) Recurrent optic neuritis and neuromyelitis optica-IgG following first and second human papillomavirus vaccinations
• (2016) Safety concerns and hidden agenda behind HPV vaccines: another generation of drug-dependent society?
• (2016) Small Fiber Neuropathy Following Vaccination |
• (2016) Two Cases of Acute Disseminated Encephalomyelitis Following Vaccination Against Human Papilloma Virus
• (2016) Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine
• (2017) Aluminium adjuvants used in vaccines versus placebo or no intervention
"Consequently, the observational studies, which based their results on registered diagnoses, may have excluded an important fraction of eligible participants with unclear adverse symptoms, as most young girls that claim to suffer from adverse events following HPV vaccination receive no clinical diagnosis, and are therefore unlikely to appear in medical registers. Moreover, the randomised clinical trials on HPV vaccines, which formed the basis for the safety assessment, have been blamed for not using true placebo (e.g. placebo not containing adjuvants) as the control intervention (Exley 2011)."
• (2017) Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia
• (2017) Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome) – An update
"From its initial presentation in 2011 to 2016 more than 4000 ASIA syndrome cases have been identified, varying from mild to severe clinical manifestations, with the majority of severe cases related to vaccines (especially against human papilloma virus ‘‘HPV’’ and seasonal influenza), silicone implants and mineral oil fillers." |
• (2017) Autoimmunity, Autonomic Neuropathy, and the HPV Vaccination: A Vulnerable Subpopulation
• (2017) Cerebral glucose metabolism changes in Japanese females following human papillomavirus vaccination: A PET study
• (2017) Critical analysis of reference studies on the toxicokinetics of aluminumbased adjuvants
"For vaccination against HPV for example, the risk of occurrence of adverse events, which may form part of one or more of the clinical entities - chronic fatigue syndrome (CFS), regional pain syndrome (RPS), orthostatic postural tachycardia syndrome (POTS) – emerges from an epidemiologic point of view." ... "For HPV vaccines, the adjuvants are Al-oxy-hydroxide for the divalent 16/18 Cervarix® (combined with a second adjuvant, monophosphoryl lipid A, detoxified derivative of lipopolysaccharide), and amorphous Al hydroxyphosphate sulfate for the quadrivalent 6/11/16/18/ Gardasil® (an adjuvant more immunostimulating than conventional aluminum-based adjuvants)."
• (2017) Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase
• (2017) EMILY TARSELL, as the Executrix of the Estate of CHRISTINA TARSELL, Petitioner, v. SECRETARY OF HEALTH AND HUMAN SERVICES, Respondent.
"Ultimately, because of the finding that Christina began to experience arrhythmia after her HPV vaccination, Ms. Tarsell has presented preponderant evidence of a logical sequence of cause and effect, connecting the HPV vaccination to the ensuing arrhythmia.
IV. Conclusion
The Court’s Opinion and Order required additional consideration consistent with the legal principles articulated by the Court for analyzing the evidence in this tragic case about a woman, Christina Tarsell, who died much too young. Under the approach dictated by the Court, Ms. Tarsell is entitled to compensation." |
• (2017) HPV-negative Gastric Type Adenocarcinoma In Situ of the Cervix: A Spectrum of Rare Lesions Exhibiting Gastric and Intestinal Differentiation
• (2017) Human papilloma virus and lupus: the virus, the vaccine and the disease
• (2017) Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France
"Our study provides reassuring results regarding the risk of AID after HPV vaccination, but an apparently increased risk of GBS [(Guillain-Barré syndrome)] was detected."
• (2017) Involvement of chronic epipharyngitis in autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA)
• (2017) New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination
• (2017) On the association between human papillomavirus vaccine and sleep disorders: Evaluation based on vaccine adverse events reporting systems
"In conclusion, although further studies are needed to confirm a correlation between administration of specific HPV vaccines and the onset of the broad spectrum of sleep disorder, the above hypothesised mechanism of action and the analysis of DBs suggest that this is not an uncommon occurrence and must be monitored."
• (2017) Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database |
• (2017) Risk of bursitis and other injuries and dysfunctions of the shoulder following vaccinations
• (2017) Safety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studies
"Racial difference may contribute to harmful responses to vaccines. A meta-analysis for safety of HPV vaccines in Asian population concluded that HPV vaccine (2vHPV or 4vHPV) had slightly higher risk of solicited local and systemic symptoms compared to controls (placebo or hepatitis vaccine)" |
• (2017) Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series
• (2017) Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld's syndrome)
• (2017) Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature
• (2017) Somatoform and neurocognitive syndromes after HPV immunization are not associated to cell-mediated hypersensitivity to aluminum
"As well as for aluminum, no immune activation against other metals is evident." ... "A hypothetical neurotoxicity of aluminum might be mediated by nano-sized particles."
• (2017) Suspected Adverse Effects After Human Papillomavirus Vaccination: A Temporal Relationship Between Vaccine Administration and the Appearance of Symptoms in Japan
• (2017) Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? |
• (2017) Vaccine-related serious adverse events might have been under-recognized in the pivotal HPV vaccine randomized trial
• (2018) A lowered probability of pregnancy in females in the USA aged 25–29 who received a human papillomavirus vaccine injection
"Results suggest that females who received the HPV shot were less likely to have ever been pregnant than women in the same age group who did not receive the shot."
• (2018) Characterization of the Differential Adverse Event Rates by Race/Ethnicity Gro
Enjoy the site? All donations are appreciated

Free Text Host is brought to you by Dagon Design
This site contains no adware, spyware, or popups
Questions? Comments?     Privacy Policy     Report abuse here